Proton 20mg

Embed Size (px)

DESCRIPTION

Package Leaflet

Citation preview

  • etaD noitaraperP .oN lairetaM

    11 TCO 50 694OP431 .oN eussI 1 fo 1 egap

    GNITEKRAMTUOYAL NGISED & TXET

    A624S194

    : yb deraperP

    _____________________ ipihoW lA dahaFrengiseD : noitisoP11 rebotcO 50 : etaD

    : yb dekcehC

    ________________________________ nafetqE dayIreganaM VP & lacideM : noitisoP11 rebotcO 50 : etaD

    : yb devorppA

    _________________________ ywaraahS lE demhArotceriD gnitekraM : noitisoP11 rebotcO 50 : etaD

    : yb dekcehC

    _____________________ imuohraB demmahoMreganaM evitaerC : noitisoP11 rebotcO 50 : etaD

    mm 012 X 841 :noisnemiD

    02

    -

    ---

    ---

    ---

    ---

    --

    ( )

    --

    --

    .

    -

    ---

    -

    -

    -

    : VIH VIH

    . .: . .

    .

    .

    . ( ) ( ). 12 .

    . 054P

    054P. :

    . .

    : :

    PB FN ( LX) PB 09 - K PSU 52 - K PB (55 - 001L)

    . :

    03. :

    02 .

    : 02 02 .

    : ( ).

    :-

    ( ).-

    .- ( ) .

    .- (

    ) . :

    : (02 ) 4

    4 .

    : 02 .

    ( ) : 02 ( ) . . 2-3 . . 4 .

    . :

    . 04

    . 02 .-

    .-

    . . :

    : . 04 .

    04 . 21 : 21

    . : . 04

    . . : 02 . 04 - 84 .

    . :

    - .- - 8

    . :

    - . .

    .- .

    - .

    05 .- .

    . :

    - .

    : - .

    : .

    . :

    ---

    . .

    . .

    .

    .

    694OP43 : 1102 .

    GM02 STELBAT NOTORP TELFAEL 694OP43

  • Material No. Preparation Date

    34PO496 05 OCT 11page 1 of 1 Issue No. 1

    MARKETINGTEXT & DESIGN LAYOUT

    491S426A

    Prepared by :

    Fahad Al Wohipi _____________________Position : DesignerDate : 05 October 11

    Checked by :

    Iyad Eqtefan ________________________________Position : Medical & PV ManagerDate : 05 October 11

    Approved by :

    Ahmed El Shaarawy _________________________Position : Marketing DirectorDate : 05 October 11

    Checked by :

    Mohammed Barhoumi _____________________Position : Creative ManagerDate : 05 October 11

    Dimension: 148 X 210 mm

    GastrointestinalDisorders

    Upper abdominal pain;Diarrhoea;Constipation;Flatulence

    Nausea/Vomiting

    Dry mouth

    -

    General disorders - - -

    Peripheral oedema

    Hepatobiliary disorders

    - - -

    Severe hepatocellular damage leading to jaundice with or without hepatic failure

    Immune system disorders - - -

    Anaphylactic reactions including anaphylactic shock

    Investigationsand others

    - - -

    Increased liver enzymes (transaminases, g-GT); Elevated triglycerides;Increased body temperature

    Musculoskeletal, connective tissue disorders

    - -Arthralgia Myalgia

    Nervous system disorders

    Headache Dizziness;Disturbances in vision (blurred vision)

    - -

    Psychiatric disorders - -

    Depression. Hallucination, Disorientation and Confusion

    -

    Renal and urinary disorders - - -

    Interstitial nephritis

    Skin and sub-cutaneous tissue disorders

    - -

    Allergic reactions such as pruritus and skin rash

    Urticaria;Angioedema;Severe skin reactions such as Stevens Johnson Syndrome, Erythema Multi-forme, Lyell-Syndrome; Photosensitivity

    DRUG INTERACTIONS :Pantoprazole decreases the systemic concentrations of the HIV protease inhibitor atazanavir, which is dependent upon the presence of gastric acid for absorption, and may result in a loss of therapeutic effect of atazanavir and the development of HIV resistance. Therefore, Pantoprazole, or other Proton pump inhibitors, should not be co-administered with atazanavir.Warfarin: There have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.No clinical significant interactions were observed with carbamazepine, caffeine, diazepam, diclofenac, ethanol, glibenclamide, metoprolol, nifedipine, phenytoin, theophylline, naproxen, piroxicam, digoxin, metazolam and oral contraceptives.No clinical significant interactions were observed with concomitantly administration of Proton with antacids, clarithromycin, metronidazole and amoxicillin.Proton may reduce the absorption of drugs whose bioavailability is pH-dependent (e.g. Ketoconazole, itraconazole and other azole anti-fungals, ampicillin esters and iron salts).Pantoprazole, as all acid- blocking medicines, may reduce the absorption of vitamin B12 (cyano- cobalamin) due to hypo- or achlorhydria. This should be considered if respective clinical symptoms are observed.Proton is metabolized in the liver via the cytochrome P450 enzyme system. An interaction of Proton with other drugs or compounds which are metabolized using the same enzyme system cannot be excluded.OVERDOSE :There are no known symptoms of overdosage, in any case, the doctor must be consulted. Management of overdose consists essentially of supportive and symptomatic treatment.PHARMACEUTICAL PARTICULARS:List of excipients: Sodium carbonate decahydrate BP, Crospovidone NF (Type XL), Mannitol BP, Povidone K-90, Calcium stearate USP, Hydroxypropyl methylcellulose, Povidone K25, Titanium dioxide, Iron oxide yellow, Propylene glycol EP, Methacrylic acid copolymer (L100-55), Triethyl citrate, Sodium Hydroxide.STORAGE :Store below 30C.PRESENTATIONS :Proton is available as 20mg gastro-resistant tablets.

    COMPOSITION :Proton 20 tablets are present as Pantoprazole sodium equivalent to 20mg pantoprazole.PHARMACOLOGICAL PROPERTIES :Pantoprazole is selective Proton pump inhibitor, substituted benz-imidazole.INDICATIONS :-- Treating mild forms of gastro-oesophageal reflux disease caused by reflux of acid

    from the stomach (with or without mild inflammation of the oesophagus). Prophylaxis of NSAID-associated gastric or duodenal ulcer, in patients with increased

    risk. Short term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adult. It

    is classified as a medical product not subjected to medical prescription regarding this indication.

    -- Long-term management of gastro-oesophageal reflux disease (inflammation of the oesophagus accompanied by the regurgitation of gastric acid) and preventing its return.

    DOSAGE AND ADMINISTRATION :Mild forms of gastro-oesophageal reflux disease :One Proton tablet (20 mg) daily in the morning for 4 weeks, followed by further 4 weeks if not fully healed.Prophylaxis of NSAID - associated gastric or duodenal ulcer in patients with increased risk of gastroduodenal complications who require continued NSAID treatment:One Proton tablet (20 mg) daily.Short term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adult:The recommended dose is 20 mg per day in case of short term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adult. It is classified as a medical product not subjected to medical prescription regarding this indication. It might be necessary to take the tablets for 2-3 consecutive days to achieve improvement of symptoms. Once complete relief of symptoms has occurred, treatment should be discontinued. The treatment should not exceed 4 weeks without consulting a doctor. If no symptom relief is obtained within 2 weeks of continuous treatment, the patient should be instructed to consult a doctor.For long-term management and for preventing the return of gastro-oesophageal reflux disease:One tablet a day.If the illness returns, the dose may be doubled, in which case you can use Pantoprazole 40 mg tablets instead, one a day. After healing, you can reduce the dose back again to one tablet (20 mg) a day.- Proton gastro-resistant tablets should not be chewed or crushed, and should be

    swallowed whole with water 1 hour before breakfast.- If you have forgotten to take Proton, do not take the dose late, but continue with

    the next regular dose on your dosing schedule.Talk to your doctor if you want to interrupt or prematurely discontinue treatment with Proton.

    SPECIFIC POPULATIONS:Elderly: No dose adjustment is necessary. However, the daily dose of 40 mg should not be exceeded. An exception is combination therapy for eradication of H. pylori, where elderly patients should receive the usual pantoprazole dose (2 x 40 mg/day) during 1 week treatment.Children below 12 years of age: Proton is not recommended for use in children below 12 years of age due to limited data in this age group.Renal impairment: No dose adjustment is necessary. However, the daily dose of 40mg should not be exceeded. For this reason, H. pylori triple therapy is not appropriate in these patients. Hepatic impairment: A daily dose of 20 mg pantoprazole should not be exceeded in patients with severe liver impairment. But in case of pantoprazole 40 mg, due to an increased AUC and a modified metabolism of pantoprazole in patients with hepatic cirrhosis, the dose regimen should be reduced to one tablet every other day. For this reason, H. pylori triple therapy is not appropriate in these patients.GENERAL INSTRUCTIONS FOR USE :* The suitable dosing and duration of therapy will be prescribed by the Physician.* As experience with long term administration in human is insufficient, treatment with

    Proton should not exceed 8 weeks, except in case of Zollinger-Ellison syndrome and other pathological hypersecretory conditions.

    PRECAUTIONS :- Proton should be used with caution in patients with severe liver impairment. The

    liver enzymes should be monitored during therapy. In case of a rise of the liver enzymes, Proton should be discontinued.

    - Before treatment, the presence of gastric or oesophageal malignancy should be excluded.

    - Increased risk of fractures of the hip, wrist, and spine has been reported in some studies of people who use Proton pump inhibitors. The greatest increased risk for these fractures was seen in those who receive high doses of these medications or use them for a years or longer and who are over 50 years of age.

    - Proton pump inhibitor (PPI) drugs may cause low serum magnesium levels (hypomagnesemia) if taken for longer than one year and can result in serious adverse events including muscle spasm (tetany), irregular heartbeat (arrhythmias) & convulsions (seizures). Magnesium supplementation alone did not improve low serum magnesium levels and the PPI had to be discontinued.

    PREGNANCy AND LACTATION :- As clinical experience in pregnant women is limited, Proton should be used

    with caution in pregnancy and breast feeding and should only be used when the potential benefits outweighs risks.

    EFFECT ON ABILITy TO DRIVE AND USE MACHINES :- There are no known effects on the ability to drive and use machines.CONTRAINDICATIONS :Known hypersensitivity to one of the constituents of Proton.Pantoprazole like other PPIs should not be co-administered with atazanavir.SIDE EFFECTS :

    Frequency

    Organ system

    Common Uncommon Rare Very rare

    Blood and lymphatic system - - -

    Leukopenia;Thrombocytopenia

    This is a medicament

    A medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.Follow strictly the doctors prescription, the method of use and the instructions of the pharmacists who sold the medicament.The doctor and the pharmacists are experts in medicine, its benefits and risks.Do not by yourself interrupt the period of treatment prescribed for you.Do not repeat the same prescription without consulting your doctor.

    Keep medicaments out of the reach of childrenCouncil of Arab Health MinistersUnion of Arab Pharmacists

    Manufactured by SPIMACOAl-Qassim Pharmaceutical Plant,Saudi Pharmaceutical Industries & Medical Appliances Corporation,Saudi Arabia.

    Revision date: March 2011.Proton is a trade mark

    34PO496

    Proton 20 TabletsPantoprazole

    34PO496 LEAFLET PROTON TABLETS 20MG